P. Verdonk (Gent-Zwijnaarde, BE)

University Hospital Antwerp Orthopaedic Surgery
Professor Dr Peter Verdonk; MD; PhD is a full time Consultant Orthopaedic Knee Surgeon at the Antwerp Orthopaedic Center (Monica Hospitals) and Researcher at the Antwerp University and the Monica Research Institute. He is also a Visiting Surgeon at the Aspetar Hospital in Doha; Qatar and an Attending Surgeon at the Antwerp University Hospital. His clinical and research interests are knee surgery and arthroplasty with a particular focus on meniscus substitution and cartilage repair. He has obtained his PhD degree at the Ghent University in 2006 on ‘The Human Meniscus: characterization; transplantation and tissue engineering. He received his orthopaedic training in Ghent University; and was a fellow of Prof. Bellemans in Leuven and of Prof. Neyret in Lyon. He has been an international traveling fellow of the International Cartilage Repair Society in 2004 and of the European Society of Sport Traumatology Knee Surgery and Arthroscopy in 2007. He is author of more than 90 peer reviewed papers and has lectured internationally. He is also involved in a number of national and international scientific organization (ICRS; ISAKOS; ESSKA; ABA; BVOT; BKS,…). For more info www.verdonk.be

Presenter Of 1 Presentation

Podium Presentation Meniscus

24.1.2 - Synthetic Medial Meniscus Replacement Superior to Non-Surgical Control: 3-Year RCT Results (Pre-Recorded)

Presentation Topic
Lecture Time
11:09 - 11:18
Potsdam 1
Session Name
Session Type
Free Papers
W. Gersoff & S. Hacker, Active Implants, Paid training instructors of the NUsurface surgical technique to new surgeons E. Hershman, Active Implants, Medical Director of MERCURY Clinical Study



This research longitudinally tests the clinical trial hypothesis that investigational subjects realize superior improvements in knee-related pain, function, and quality of life, to control subjects, through 3 years of follow-up.

Methods and Materials

242 subjects (176 investigational, 66 control) treated in 2 prospective, concurrent clinical trials in the U.S., and pooled for analysis. Subjects had persistent knee pain and one or more previous partial meniscectomies at least 6 months before trial entry. Patient-reported knee pain, function, and quality of life were assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Treatment cessation was defined as any investigational subject discontinuing the per-protocol treatment by permanent prosthesis removal, or control subjects undergoing any surgical procedure on the index knee. The investigational and control cohorts analyzed were compared at each time point using a two tailed t-test.


The magnitude of improvement from baseline to 3 years was statistically superior in the investigational cohort, compared to the control cohort for all 6 KOOS subscales (Figure 1). Improvement in KOOS Overall and KOOS Pain for the investigational and control cohorts at 3 years were 26.4 vs 10.4 points, and 26.9 vs 15.4 points, respectively. Controls experienced a 35% decline in KOOS Overall improvement between the 2-year and 3-year timepoint (15.9 declined to 10.4). Treatment cessation through 3 years was 31% higher in the control cohort than the investigational cohort (19.6% vs.15.0%).

2022 icrs figure 1.png


Results demonstrate statistically and clinically significant superiority for relief of knee pain and improvement in function compared to non-surgical care alone. Between 2 and 3 years, NUsurface KOOS scores remained stable, while Controls regressed. The magnitude of change from baseline to 3 years remained superior for the investigational cohort, even when accounting for subjects undergoing device exchange or repositioning.